Galimedix, Inc. | WebDisclosure

Basculer en Français

10417	Companies
218087	Keywords
147640	Articles
115400	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 05/06/2025 at 14:00, 1 year ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year 1 month ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year 1 month ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year 1 month ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year 1 month ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year 1 month ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year 1 month ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 4 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 4 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 4 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Accesswire

Published on 05/18/2026 at 22:30, 33 minutes ago

Ondas Inc. Stockholders: Vote Now to Ensure Quorum for Annual Meeting
Published on 05/18/2026 at 14:37, 8 hours 26 minutes ago

Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization
Published on 05/18/2026 at 14:30, 8 hours 33 minutes ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Published on 05/18/2026 at 08:01, 15 hours 2 minutes ago

Result of Fundraise
Published on 05/17/2026 at 15:20, 1 day 7 hours ago

China XLX Announces 2026 Q1 Results

View all ACCESSWIRE

EQS Group

Published on 05/18/2026 at 20:54, 2 hours 9 minutes ago

Freelance.com: chiffre d’Affaires 1er trimestre 2026 : 275,3 M€ (+4%)
Published on 05/18/2026 at 20:40, 2 hours 23 minutes ago

Aramco and Pasqal launch Saudi Arabia's first Quantum Computer and Middle East's first commercial Quantum Computing as a Service platform
Published on 05/18/2026 at 20:35, 2 hours 28 minutes ago

Africa Finance Corporation Approves US$100 Million Commitment to Africa-Focused Technology Fund Managers to Accelerate Africa’s Digital Industrialisation
Published on 05/18/2026 at 19:38, 3 hours 25 minutes ago

Holding(s) in Company
Published on 05/18/2026 at 19:00, 4 hours 3 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 11 MAI 2026 au 15 MAI 2026

Les Echos

Published on 05/18/2026 at 22:25, 38 minutes ago

Résultats de l’offre publique de retrait et mise en œuvre du retrait obligatoire à venir sur les titres TERACT
Published on 05/18/2026 at 22:25, 38 minutes ago

Results of the public buy-out offer and implementation of the subsequent squeeze-out of TERACT shares
Published on 05/18/2026 at 18:36, 4 hours 27 minutes ago

Déclaration des transactions sur actions propres réalisées du 11/05/2026 au 17/05/2026
Published on 05/18/2026 at 18:30, 4 hours 33 minutes ago

ALPOU - Groupe POULAILLON - Dépôt du projet de note en réponse à l'offre publique d'achat simplifiée
Published on 05/18/2026 at 18:23, 4 hours 40 minutes ago

260518 BENETEAU Transactions sur actions propres

View all LES ECHOS COMFI WIRE